Ascentage Pharma Group International
AAPG26.980USD
-0.900-3.23%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Ascentage Pharma Group International Company
Ascentage Pharma Group International is an investment holding company primarily engaged in the discovery, development, and commercialization of therapies for hematologic malignancies. The Company's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The Company's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), and multiple myeloma (MM). The Company primarily conducts its businesses in domestic market.
Ascentage Pharma Group International Info
Ticker SymbolAAPG
Company nameAscentage Pharma Group International
IPO dateOct 28, 2019
CEOYang (Dajun)
Number of employees- -
Security typeDepository Receipt
Fiscal year-end- -
Address68 Xinqing Road, Suzhou Industrial Park
CitySUZHOU
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code- -
Phone
Websitehttps://www.ascentage.cn/
Ticker SymbolAAPG
IPO dateOct 28, 2019
CEOYang (Dajun)
Company Executives of Ascentage Pharma Group International
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Wei Ren
Mr. Wei Ren
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Jin Cao
Mr. Jin Cao
Head - Finance
Head - Finance
--
--
Dr. Dazhong (Simon) Lu, Ph.D.
Dr. Dazhong (Simon) Lu, Ph.D.
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Dajun Yang, M.D., Ph.D.
Dr. Dajun Yang, M.D., Ph.D.
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
Executive Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Changqing Ye
Mr. Changqing Ye
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. Raymond Jeffrey (Jeff) Kmetz
Mr. Raymond Jeffrey (Jeff) Kmetz
Chief Business Officer
Chief Business Officer
--
--
Mr. Thomas Joseph (Tom) Knapp, J.D.
Mr. Thomas Joseph (Tom) Knapp, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
,
,
Senior Vice President - Global Corporate Development and Finance
Senior Vice President - Global Corporate Development and Finance
--
--
Veet Misra
Veet Misra
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Yifan Zhai, M.D., Ph.D.
Dr. Yifan Zhai, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
0.02%
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
Other
99.92%
Shareholders
Shareholders
Proportion
UBS Financial Services, Inc.
0.02%
XY Capital Ltd.
0.02%
Point72 (DIFC) Ltd
0.02%
NEOS Investment Management, LLC
0.01%
Tema ETFS LLC
0.01%
Other
99.92%
Shareholder Types
Shareholders
Proportion
Investment Advisor
0.08%
Hedge Fund
0.01%
Other
99.91%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
23
89.21K
0.29%
--
2025Q3
23
89.21K
0.29%
+6.09K
2025Q2
16
82.77K
0.27%
-154.43K
2025Q1
6
237.19K
0.00%
+237.19K
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
UBS Financial Services, Inc.
7.36K
0.01%
+4.88K
+196.89%
Jun 30, 2025
XY Capital Ltd.
5.59K
0.01%
-17.91K
-76.22%
Jun 30, 2025
Point72 (DIFC) Ltd
20.89K
0.02%
-4.51K
-17.77%
Jun 30, 2025
NEOS Investment Management, LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
Tema ETFS LLC
15.49K
0.02%
+15.49K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
361.00
0%
--
--
Aug 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
0.43%
Invesco Golden Dragon China ETF
0%
Tema Oncology ETF
Proportion0.43%
Invesco Golden Dragon China ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Ascentage Pharma Group International?
The top five shareholders of Ascentage Pharma Group International are:
UBS Financial Services, Inc. holds 7.36K shares, accounting for 0.01% of the total shares.
XY Capital Ltd. holds 5.59K shares, accounting for 0.01% of the total shares.
Point72 (DIFC) Ltd holds 20.89K shares, accounting for 0.02% of the total shares.
NEOS Investment Management, LLC holds 15.49K shares, accounting for 0.02% of the total shares.
Tema ETFS LLC holds 15.49K shares, accounting for 0.02% of the total shares.
UBS Financial Services, Inc. holds 7.36K shares, accounting for 0.01% of the total shares.
XY Capital Ltd. holds 5.59K shares, accounting for 0.01% of the total shares.
Point72 (DIFC) Ltd holds 20.89K shares, accounting for 0.02% of the total shares.
NEOS Investment Management, LLC holds 15.49K shares, accounting for 0.02% of the total shares.
Tema ETFS LLC holds 15.49K shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Ascentage Pharma Group International?
The top three shareholder types of Ascentage Pharma Group International are:
UBS Financial Services, Inc.
XY Capital Ltd.
Point72 (DIFC) Ltd
UBS Financial Services, Inc.
XY Capital Ltd.
Point72 (DIFC) Ltd
How many institutions hold shares of Ascentage Pharma Group International (AAPG)?
As of 2025Q4, 23 institutions hold shares of Ascentage Pharma Group International, with a combined market value of approximately 89.21K, accounting for 0.29% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Ascentage Pharma Group International?
In --, the -- business generated the highest revenue for Ascentage Pharma Group International, amounting to -- and accounting for --% of total revenue.
